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Summary

Background Group B streptococcus (GBS) colonisation during pregnancy can lead to invasive GBS disease (iGBS) in
infants, including meningitis or sepsis, with a high mortality risk. Other outcomes include stillbirths, maternal
infections, and prematurity. There are data gaps, notably regarding neurodevelopmental impairment (NDI), especially
after iGBS sepsis, which have limited previous global estimates. In this study, we aimed to address this gap using
newly available multicountry datasets.
Methods We collated and meta-analysed summary data, primarily identified in a series of systematic reviews published
in 2017 but also from recent studies on NDI and stillbirths, using Bayesian hierarchical models, and estimated the
burden for 183 countries in 2020 regarding: maternal GBS colonisation, iGBS cases and deaths in infants younger
than 3 months, children surviving iGBS affected by NDI, and maternal iGBS cases. We analysed the proportion of
stillbirths with GBS and applied this to the UN-estimated stillbirth risk per country. Excess preterm births associated
with maternal GBS colonisation were calculated using meta-analysis and national preterm birth rates.
Findings Data from the seven systematic reviews, published in 2017, that informed the previous burden estimation (a
total of 515 data points) were combined with new data (17 data points) from large multicountry studies on
neurodevelopmental impairment (two studies) and stillbirths (one study). A posterior median of 19·7 million
(95% posterior interval 17·9–21·9) pregnant women were estimated to have rectovaginal colonisation with GBS in
2020. 231 800 (114 100–455 000) early-onset and 162 200 (70 200–394 400) late-onset infant iGBS cases were estimated
to have occurred. In an analysis assuming a higher case fatality rate in the absence of a skilled birth attendant,
91 900 (44 800–187 800) iGBS infant deaths were estimated; in an analysis without this assumption, 58 300
(26 500–125 800) infant deaths from iGBS were estimated. 37 100 children who recovered from iGBS (14 600–96 200)
were predicted to develop moderate or severe NDI. 40 500 (21 500–66 200) maternal iGBS cases and 46 200
(20 300–111 300) GBS stillbirths were predicted in 2020. GBS colonisation was also estimated to be potentially
associated with considerable numbers of preterm births.
Interpretation Our analysis provides a comprehensive assessment of the pregnancy-related GBS burden. The Bayesian
approach enabled coherent propagation of uncertainty, which is considerable, notably regarding GBS-associated
preterm births. Our findings on both the acute and long-term consequences of iGBS have public health implications
for understanding the value of investment in maternal GBS immunisation and other preventive strategies.
Funding Bill & Melinda Gates Foundation.
Copyright © 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.

Introduction
Neonatal infections are a major contributor to the global
burden of diseases, with an estimated 6·9 million
incident cases of presumed severe neonatal infections
each year in low-income and middle-income countries
alone, causing approximately half a million deaths
worldwide in 2012.1 One of the leading pathogens causing
these infections is group B streptococcus (GBS),2,3 which
has been recognised for more than 5 decades4,5 as causing
invasive GBS (iGBS) disease in young infants, with a
high case fatality rate. A systematic review, published in
www.thelancet.com/lancetgh Vol 10 June 2022

2012, described the iGBS incidence in infants for several
regions,6 and the first set of global estimates for GBS,3,7
including maternal GBS disease,8 stillbirths due to GBS,9
and an association between preterm birth and GBS
colonisation,10 were published in 2017 using data for 2015.
In the context of the UN call for expanding effective
preventive interventions targeting the main causes of
neonatal mortality,11 an updated and comprehensive
estimation of the full GBS burden is necessary to guide
and accelerate the development of improved preventive
strategies, including maternal GBS vaccines.12,13
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Research in context
Evidence before this study
A previous study by Seale and colleagues estimated the global
group B streptococcus (GBS) burden, including several outcomes
that affect public health. The study quantified that GBS affected
21·7 million pregnant women globally in the year 2015 and, by
applying a compartmental model with sequential risks, it
predicted 319 000 cases of invasive GBS (iGBS) disease and
90 000 (95% uncertainty range, 36 000–169 000) deaths during
early infancy. That study highlighted major data gaps, notably
regarding neurodevelopmental impairment (NDI) in children
who recovered from iGBS. Preterm birth associated with GBS
was not estimated. We searched PubMed for studies on the
global burden of GBS, published in English, up to Aug 1, 2021,
using the search terms (Group B Streptococcus OR Streptococcus
agalactiae) AND (global or worldwide or international) AND
(burden OR incidence OR mortality OR morbidity OR burden OR
prevalence OR survival) and found no other relevant papers. We
also searched for data on GBS-related stillbirths and NDI after
iGBS up to Feb 1, 2021, and included newly available published
and unpublished data on these outcomes.
Added value of this study
Our new estimates for 2020 include a synthesis of data for each
GBS outcome, including published and unpublished data, with
specifically designed data collection on long-term NDI outcomes
in both low-income and high-income settings. Our study
included the largest data input yet on GBS, to the best of our
knowledge, suppporting some of the findings of the previous
study, notably the high number of women with GBS
colonisation (~20 million), infant iGBS cases (231 000 earlyonset and 162 000 late-onset cases), and deaths caused by early
infancy iGBS in every region (91 000), with a disproportionate
burden in sub-Saharan Africa. Our findings for these outcomes
are similar to those from the last study, despite differences in
statistical approaches. Notably, we also estimated the risk of NDI

A notable gap identified in earlier estimates of the GBSrelated burden of disease was the associated risk of
neurodevelopmental impairment (NDI), with no data
available to estimate the risk of NDI after iGBS sepsis,
and few data on NDI after iGBS meningitis.14 In 2021,
data on GBS sepsis, a more frequent clinical presentation
of this infection compared with meningitis, have been
published: a large cohort study in Denmark and the
Netherlands showed that GBS sepsis also leads to an
increase in NDI risk and special education needs.15 In
addition to these direct consequences of invasive
infections, maternal GBS colonisation has also been
associated with preterm births.10,16 An association between
GBS colonisation and preterm birth should be considered,
given that prematurity causes deaths and disability in
every region.17
In this study, we aimed to advance the estimates of the
GBS burden from the year 20157 by updating the

after iGBS sepsis, not just after meningitis, based on new data
on NDI among patients with iGBS from an electronic cohort in
Denmark and five low-income and middle-income countries
(Argentina, India, Kenya, Mozambique, and South Africa),
which increased the estimated annual number of patients
recovering from moderate or severe NDI. The estimated number
of stillbirths due to GBS is notable (46 000) and crucial to count.
We also estimated, for the first time, the potential preterm
burden associated with GBS. Although this is potentially
substantial, at more than 0·5 million cases, there is wide
uncertainty, and it still represents a small proportion (3·5%) of
the overall preterm birth burden, at 15 million births per year.
Implications of all the available evidence
Our findings show a higher burden of iGBS than previously
estimated, primarily because of the previously unquantified
number of NDI cases after GBS sepsis. We note that, even in
regions with good coverage of intrapartum antibiotic
prophylaxis, antibiotic prophylaxis, usually given around the
time of birth, is unlikely to prevent most stillbirths, GBSassociated preterm birth, or late-onset iGBS, which is more
likely to present as meningitis and has a high risk of NDI.
Notably, a high proportion of the burden is in low-income and
middle-income countries, where intrapartum antibiotic
administration is more challenging to implement. Data gaps in
this area that are a priority require more ambitious studies; for
example, multicountry pregnancy cohort studies from the first
trimester with more frequent testing of GBS colonisation could
improve data for GBS-associated preterm risk as well as GBS
stillbirths and maternal sepsis, which have been understudied
in all settings. Our results will enable the first global costeffectiveness analysis for maternal GBS vaccination and provide
an imperative for more rapid progress given several decades of
vaccine development so far.

estimated burden for 2020, including more input data
from novel studies, and applying a different statistical
approach to estimate, for 183 countries, the numbers of:
(1) cases of maternal colonisation, (2) iGBS cases in the
first 3 months of life, (3) deaths among infants with
iGBS, (4) patients who recovered from iGBS with NDI,
(5) stillbirths caused by GBS, (6) cases of maternal iGBS,
and (7) excess preterm births associated with maternal
GBS colonisation. Throughout the manuscript we
highlight key data gaps, explain assumptions, and
discuss the limitations of our approach, in line with
recommended estimation practices.18

Methods
Overview

We collated aggregated data for all outcomes (cases of
maternal colonisation, iGBS cases in the first 3 months
of life, deaths among infants younger than 3 months
www.thelancet.com/lancetgh Vol 10 June 2022
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with iGBS, patients who recovered from iGBS with NDI,
stillbirths caused by GBS, cases of maternal iGBS, and
excess preterm births associated with maternal GBS
colonisation). Most studies included were identified in a
series of systematic reviews published in 2017,3,7–10,14,19–21
and we included new data on stillbirths and NDI. Note
that the search strategy, selection criteria, data extraction,
and assessment of study quality were described in the
original publications of these systematic reviews.
Bayesian hierarchical models22 were used to analyse the
evidence. We estimated the absolute burden for 2020 on
the basis of the country-specific numbers of births in the
UN World Population Prospects 2019 for 183 countries
included in the dataset based on population size (only
countries with 90 000 or more inhabitants were listed).
All relevant outcomes were studied as shown in figure 1
and panel 1, with predefined case definitions. Bayesian
models allowed a coherent propagation of uncertainty in
the estimation of the burden and accounted for the
multilevel structure of the data (eg, for several outcomes,
multiple studies were identified per region). Posterior
medians and intervals (95% posterior intervals) were
reported that account for the uncertainty in the parameter
estimation; relevant sensitivity analyses were also
reported. Parameters were estimated either at the country
(eg, maternal colonisation), regional (eg, case fatality
rate), or global (eg, risk of NDI after GBS meningitis)
levels, depending on data availability (appendix pp 4–22).
Details on the statistical models, including assumptions
and prior probability distributions, are in the appendix
(pp 4–22). Our estimation process followed the
GATHER statement.18 Results are shown by Sustainable
Development Goals regions.

Maternal GBS colonisation
GBS colonisation of the maternal genitourinary tract
is associated with early-onset iGBS (EOGBS)24,25 and
quantification of its frequency is a key step in the
estimation process. We included data from a systematic
review,23 and developed a hierarchical model to regress
country-level maternal GBS colonisation prevalence
on country-level covariates.26 Using this approach, we
estimated the colonisation prevalence in pregnant
women for countries with and without GBS colonisation
data, adjusting for study differences (appendix pp 4–5) in
terms of the swab site and laboratory diagnostics, and
accounting for parameter uncertainty.

EOGBS and late-onset iGBS (LOGBS)
iGBS in infants might present as EOGBS (0–6 days) or
LOGBS (7–89 days), and clinical syndromes include sepsis
or meningitis (figure 1, panel 1). Given that routine
surveillance data might underestimate EOGBS in most
settings, as argued previously by Edmond and colleagues6
and Dagnew and colleagues,27 here we estimated the risk
of EOGBS in neonates born to mothers who were GBS
colonised. For modelling EOGBS risk, it was essential to
www.thelancet.com/lancetgh Vol 10 June 2022
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Figure 1: Overview of GBS colonisation in pregnancy and relevant outcomes
During pregnancy, GBS can cause stillbirths, be associated with prematurity, and lead to maternal infection or,
more rarely, death. Some newborn babies born to mothers who are GBS colonised develop invasive disease during
the first week of life. Infants can also develop GBS disease between days 7 and 89. The fatality risk is high, and
depends on adequate access to care. Of those children who survive the acute episode, some will be diagnosed with
neurodevelopmental impairment. Neurodevelopmental impairment risks after GBS meningitis and GBS sepsis
differ and were modelled separately. This figure was adapted from a study by Lawn and colleagues, with
permission.3 GBS=group B streptococcus.

consider intrapartum antibiotic prophylaxis use; hence
we developed a model to regress study-level EOGBS risk
in babies of mothers who were GBS colonised who
received intrapartum antibiotic prophylaxis.219 We used
this regression in combination with national coverage
data on intrapartum antibiotic prophylaxis, based
primarily on a review with data for 92 countries,20 plus
additional assumptions for those countries without data
(appendix pp 6–7): we assumed 0% intrapartum antibiotic
prophylaxis coverage in low-income countries and 80%
coverage in high-income countries with no coverage data
(appendix pp 6–7). In a secondary analysis, we used a
Bayesian evidence synthesis model26 to combine data
from studies directly assessing EOGBS incidence and
studies estimating the risk of EOGBS among infants of
mothers who were GBS colonised.
Similar to EOGBS, cases of LOGBS are likely to be
under-reported in surveillance systems. Hence, we used
an approach similar to a previous analysis21 and estimated
region-specific proportions of LOGBS compared with
EOGBS, which provided a multiplication factor to apply
to EOGBS estimates. Full details are in the appendix
(pp 6–9).

For the UN World Population
Prospects 2019 see
https://population.un.org/wpp/
See Online for appendix

Deaths among infants with iGBS
Since most EOGBS cases (68%) occur within 24 h of
birth,21 we assumed a high case fatality rate of 90%,
using similar assumptions to Seale and colleagues,7 for
EOGBS cases without skilled birth attendance (a marker of
low access to any health care, including antibiotic
e809
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Panel 1: Case definitions used for estimates3,7–10,14,19–21,23
• Group B streptococcus (GBS) maternal colonisation: isolation by culture of GBS from
either the vagina (high or low), rectum, or peri-anal region at any time during
pregnancy
• Maternal GBS disease: laboratory isolation of GBS from sterile site in pregnant or postpartum women (up to 42 days post partum), with clinical signs of sepsis
• Stillbirth GBS invasive disease: birth of a fetus weighing >1000 g or ≥28 weeks'
gestational age, or both, with no signs of life and evidence of GBS invasive disease from
a normally sterile site such as foetal blood, lung aspirate, or cerebrospinal fluid
• Neonatal and infant GBS invasive disease: laboratory isolation of Streptococcus agalactiae
from a normally sterile site in an infant aged 0–89 days with signs of clinical disease,
including meningitis, sepsis, or bacteraemic pneumonia
• Neurodevelopment impairment in children after GBS invasive disease: cognitive or
motor, vision, or hearing, or a combination, impairment in patients who have
recovered from invasive infant GBS disease isolated from a normally sterile site
• Preterm birth associated with GBS maternal colonisation: delivery before completion
of 37 weeks of gestation from a mother with maternal GBS colonisation isolated from
vaginal, cervical, or rectal swabs, or a combination

treatment). A dataset from UNICEF and WHO on countrylevel skilled birth attendance was used.28 For cases of
patients with EOGBS with skilled birth attendance and all
cases of LOGBS, we applied case fatality rates estimated by
region on the basis of published literature (appendix
pp 10–12). Assuming a fixed high mortality rate (of 90%)
for cases of EOGBS without skilled birth attendance
means that uncertainty in this parameter, which is key in
the estimation of number of deaths, is not incorporated in
the estimates. We also undertook a sensitivity analysis that
considered the scenario that EOGBS without skilled birth
attendance could have the same regional case fatality rate
as EOGBS with skilled birth attendance.

Long-term moderate or severe NDI among patients
who recovered from iGBS

For the CHAMPS network see
https://champshealth.org

For the Global Health
Observatory data repository see
https://www.who.int/data/gho
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iGBS can lead to NDI in those who recover. In this
analysis, we estimated the risk of moderate and severe
impairments, which is more likely to be consistent across
settings and study designs compared with milder NDI
types; in the appendix (pp 15–16), we present the results of
analyses that also considered mild NDIs. For meningitis,
we used studies reviewed in 2017,14 novel data from a
national cohort in Denmark (which included children
with outcome data available at the age of 10 years),15 and
reanalysis of data from a multicentre observational study29
performed in Argentina, India, Mozambique, Kenya, and
South Africa including all meningitis cases, irrespective of
age (4–17 participants in each centre, with a total of
38 participants); that study was performed as part of this
research project. For GBS sepsis, we used data from the
same study in Denmark (805 children with data at the age
of 10 years) and four smaller studies (4–61 participants
in each study, with a total of 109 participants), also
reviewed in a systematic review by Kohli-Lynch and
colleagues,14 for high-income countries; for low-income

and middle-income countries, data from the afore
mentioned multicentre study were used (22–31 partici
pants in each centre, with a total of 108 participants) in a
separate meta-analysis. Note that data from the
Argentinian site in the multicentre study were not
included because the low proportion of identified patients
who recovered from iGBS who were assessed might have
been linked to selection bias. Definitions of NDI,
including of moderate and severe presentations, are
described in detail in these previous studies;14,15,30 both the
Danish study and the multicentre study, done as part of
this project, used multidomain definitions consistent with
the Global Burden of Disease, Injuries, and Risk Factors
Study.31 Since most of these studies did not include
comparator groups, our analysis does not estimate the
association between iGBS and NDI, but rather the risk of
moderate and severe NDI in patients who recovered from
iGBS. Hence, to estimate the number of NDI cases
attributable to iGBS, we used the risk of moderate or
severe NDI in children without a history of iGBS in the
Danish study (2·1%) as a conservative estimate of the
comparative risk. Although the Danish cohort is the largest
to date, and included information into the second decade
of life, it is probable that the counterfactual risk varies
considerably within and between countries. Similar to the
EOGBS case fatality rate in children with no access
to skilled birth attendance, this counterfactual risk was
assumed to be fixed; hence estimates do not incorporate
uncertainty in this parameter. Another assumption is that
the risk of NDI estimated in these analyses represents
a lifelong risk, which is probably an underestimation,
because most studies recruited children younger than
10 years.

Stillbirths due to GBS
Data inputs included a literature review on the proportion
of stillbirths with evidence of GBS infection, with six
studies published after 2000, one of which also included
data collected before that year.9 We updated the searches
and identified no additional published studies, but were
able to add unpublished data from the Child Health
and Mortality Prevention Surveillance (CHAMPS)
network32 including seven study sites in Africa and Asia,
corresponding to a total of 509 stillbirths. In the
CHAMPS network, a panel of local experts evaluated
all data available for stillbirths enrolled with a postmortem investigation including clinical information and
collection and testing of tissue and non-tissue specimens
to establish whether GBS was involved in the causal
chain leading to each stillbirth. We applied a hierarchical
model to combine data within regions. For regions with
no studies, we used the model to predict the proportion.
Region-specific proportions of stillbirths caused by GBS
were then applied to country-specific stillbirth risk from
the Global Health Observatory data repository.Sensitivity
analyses with different prior assumptions were included
in the appendix (p 42).
www.thelancet.com/lancetgh Vol 10 June 2022
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Maternal iGBS
GBS also causes disease in pregnant women. The little
research on this, all from high-income countries, was
reviewed by Hall and colleagues.8 We used data reported
in that review, together with those from a study in
England,33 to estimate the risk of GBS-related morbidity
during pregnancy or post partum (up to 42 days after
delivery). Of note, the inclusion of the 2020 study in
England was not the result of a systematic search but was
suggested by the project’s Scientific Advisory Group.
Since these studies, which primarily reported cases
where GBS was cultured from blood or cerebrospinal
fluid, or both, did not estimate risk given maternal GBS
carriage, we applied our estimates directly to countryspecific number of births.

Excess preterm births associated with maternal GBS
colonisation
Using previously reported data,10 we estimated the
association between maternal GBS colonisation and
preterm births. To incorporate all available evidence,34 we
performed a meta-analysis on case-control studies and
used the posterior distribution of the coefficient as a
prior distribution in a meta-analysis model of cohort and

cross-sectional studies. The overall odds ratio was used,
together with country-level frequencies of preterm
births,35 to calculate the excess number of preterm births
associated with maternal GBS colonisation. Two different
approaches were used for this calculation, which also
required estimated country-level prevalence of maternal
GBS colonisation; in the appendix (pp 21–22), we present
the results of the meta-analyses and describe these
approaches.

Bayesian models
All analyses were done using the Hamiltonian Monte
Carlo algorithm in PyStan (version 2.19), the interface for
the Stan libraries in Python (version 3.7).36 Details on the
models are presented in the appendix (pp 4–22, 43),
including additional assumptions in our analyses and
probable limitations.

Study ethics approval
For the primary data collection in high-income, lowincome, and middle-income countries, the overarching
protocol for the observational study was granted ethics
approval at the London School of Hygiene & Tropical
Medicine (approval number 16246). Institutional review

Parameter(s) modelled

Data included

Input data overview

Level of
estimation

Maternal GBS
colonisation

Prevalence

325 studies from 82 countries23

Number of studies per country: median, 2 (range, 1–31); number of study
participants: 349 (35–17 430); number of mothers who are GBS
colonised: 48 (1–2911); and publication date range: 1981–2016

Country

EOGBS risk

Risk of EOGBS in babies born to
mothers who were GBS colonised
(regression used to measure this
risk using intrapartum antibiotic
prophylaxis covariate)

28 studies assessing the risk of EOGBS in Number of studies done in high-income countries: 23; number of
babies born to mothers who were GBS
mothers who are GBS colonised per study: median, 450 (range,
colonised19
216–3819); number of EOGBS cases in each study: 2 (0–24); publication
date range: 1979–2016

Country

LOGBS risk

Proportion of all iGBS cases that
are LOGBS

20 studies that directly assess both
EOGBS and LOGBS incidence21

Number of studies per region: range, 1–12; number of GBS cases per
study: median, 114 (range, 15–856); publication date range: 2002–16

Region

Death among infants
with iGBS

Case fatality rates for EOGBS and
LOGBS cases

47 studies were used to estimate the
case fatality rate for EOGBS cases and 29
studies were used to estimate the case
fatality rate for LOGBS cases21

Number of studies per region: EOGBS range, 7–19, and LOGBS range, 3–14;
number of GBS cases per study: EOGBS median, 21 (range, 1 – 517), and
LOGBS median, 43 (range, 3–373); publication date range: 2002–16

Region

Patients who
recovered from iGBS
(meningitis) with NDI

Risk of moderate or severe NDI in
those who recovered from iGBS
(meningitis)

20 studies14

Number of study participants: range, 4–103; number of children with
moderate or severe NDI: range, 0–30; publication date range: 1982–2022

Global

Patients who
recovered from iGBS
(sepsis) with NDI

Risk of moderate or severe NDI in
those who recovered from iGBS
(sepsis)

Nine studies (five in high-income
countries and four in low-income and
middle-income countries)14,15

Number of study participants: median, 36 (range, 4–805) in high-income Region
countries; range, 22–31 in low-income and middle-income countries;
number of children with moderate or severe NDI: range, 0–31; publication
date range: 1974–2022

Stillbirths due to GBS

Proportion of stillbirths with
evidence of GBS infection

Data from six studies done after 2000,
in addition to data from the CHAMPS
network on seven local studies
(ten countries in total)9,32

Number of studies done in Africa: nine; number of studies done in Asia
(Bangladesh): one; number of stillbirths investigated: median, 80 (range,
18–5175); number of GBS-related stillbirths: 2 (0–37); publication date
range: 2001–17 (and unpublished data)

Maternal iGBS

Risk of GBS-related maternal
disease

Five studies8,33

Number of study participants: median, 150 043 (range, 59 491–1 327 556); Global
number of maternal cases: 57 (8–493); publication date range: 2013–20

Excess preterm births
associated with
maternal GBS
colonisation

Odds ratio of the association
between preterm births and
maternal GBS colonisation

Nine case-control studies and 28 cohort
and cross-sectional studies10

Number of study participants: case-control studies median, 206 (range,
82–329), and cohort or cross-sectional studies: 998 (62–216 132); number
of preterm births: case-control studies 84 (37–151), and cohort or crosssectional studies 90 (3–17 018); publication date range: 1982–2016

Region

Global

For more details of input data see the appendix. EOGBS=early-onset iGBS. GBS=group B streptococcus. iGBS=invasive GBS. LOGBS=late-onset iGBS. NDI=neurodevelopmental impairment.

Table 1: Summary of the input data for the estimation for each parameter relevant to GBS burden in pregnancy and infancy
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institutional review board of WHO (approval number
ERC.0003169). The Danish electronic cohort study was
approved by the Danish Data Protection Agency (record
number 2015–57–0002). In the Netherlands, the study
protocol (EPI-408) was submitted to the Centre for
Clinical Expertise at the National Institute for Public
Health and the Environment. The study protocol was
exempted from further approval by an ethics research
committee, according to Dutch law for medical research
involving human patients. This study was reviewed by the
Centers for Disease Control and Prevention and was
conducted consistent with applicable federal law and
Centers for Disease Control and Prevention policy.
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Figure 2: Global burden of outcomes related to GBS in pregnancy and infancy
(A) Number of pregnant women who were GBS colonised by Sustainable Development Goal regions. The height of
the orange bars represents the median, and 2·5–97·5%, 25–70%, and 40–60% percentile intervals are presented by
error bars with different widths. The blue bars correspond to the total number of births in each region.
(B) Estimated global burden of GBS cases, deaths, and NDIs. In the top panel, global numbers (posterior median
and 95% percentile interval) of patients with iGBS (maternal, EOGBS, and LOGBS) are shown. The bottom left plot
presents the number of children estimated to develop moderate and severe NDI after iGBS in 2020; and the
bottom right panel shows the estimated numbers of stillbirths and deaths in infants with iGBS in 2020. In the top
panel, EOGBS (2) corresponds to estimates that included both direct and indirect data on incidence; and in the
bottom right panel, deaths (2) corresponds to the sensitivity analysis that did not assume a higher mortality in
EOGBS cases in the absence of skilled birth attendance. EOGBS=early-onset iGBS. GBS=group B streptococcus.
iGBS=invasive GBS. LOGBS=late-onset iGBS. NDI=neurodevelopmental impairment.

boards in each of the countries granted ethics approval
(Argentina approval number protocol EGB-1; India
approval numbers 11723 [Christian Medical College
Vellore], 2019–7034 [Indian Council of Medical Research];
Kenya approval number SERU/CGMR-C/164/3882;
Mozambique approval number 98/CNBS/2019; and
South Africa approval number M190241), as well as the
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The funder of the study had no role in study design, data
collection, data analysis, data interpretation, or writing of
the report.
Input data per parameter are summarised in table 1.
Maternal GBS colonisation had the most data, in terms
of number of studies, and subsequent variables have
fewer inputs, notably maternal infection and stillbirths.
Some regions are markedly under-represented; for
example, only one study was identified on GBS diagnosis
in stillbirths in Asia (Bangladesh), with none from Asia
for maternal infection. Most studies assessing the risk of
EOGBS in babies born to mothers who were GBS
colonised and all studies on GBS-related maternal
morbidity were from high-income countries.
19·7 million (95% posterior interval, 17·9–21·9)
pregnant women were estimated to be colonised with
GBS globally in 2020, with the highest numbers in
sub-Saharan Africa (6·1 million [5·2–7·2]) and central
and south Asia (4·4 million [3·7–5·2]; figure 2A;
appendix pp 35–36). After accounting for intrapartum
antibiotic prophylaxis policy coverage,7,20 we estimated
231 800 (114 100–455 000) neonates developed EOGBS,
with 90 800 (43 000–186 600) cases estimated to occur
in sub-Saharan Africa, and 4300 (2000–7600) in Europe
and north America (table 2). In a secondary analysis
for the same countries, which included both direct and
indirect evidence on incidence, the estimated number
of global EOGBS cases was 222 500 (138 000–353 300;
appendix p 37). Using region-specific proportions of
iGBS cases presenting as LOGBS (appendix p 38), we
estimated that 162 200 (70 200–394 400) infants
developed LOGBS (table 2). Figure 3A shows the
relative distribution of infant and maternal GBS cases
by region. We present the combined incidence of
EOGBS and LOGBS cases in different regions in the
appendix (p 24).
Assuming a higher case fatality rate in the absence
of a skilled birth attendant, an estimated 91 900
(44 800–187 800) deaths occurred in infants with either
EOGBS or LOGBS globally (figure 2B, 3B; table 2;
www.thelancet.com/lancetgh Vol 10 June 2022
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Stillbirths
Sub-Saharan Africa

EOGBS

LOGBS

Infant deaths after iGBS
(both EOGBS and LOGBS)

20 300 (9000–40 500)

90 800 (43 000–186 600)

78 100 (30 000–218 700)

2300 (1000–5800)

29 000 (13 800–58 700)

20 800 (8400–52 800)

9600 (4300–20 800)

Central and south Asia

14 700 (3600–51 500)

47 300 (24 300–89 900)

23 600 (6100–68 600)

16 700 (8200–33 500)

East and southeast Asia

4600 (1100–16 200)

45 700 (21 600–92 900)

22 600 (5700–68 200)

Latin America and the Caribbean

1800 (300–11 700)

12 800 (6700–24 400)

North Africa and west Asia

Oceania

100 (20–600)

Europe and North America

700 (200–1800)

Global

46 200 (20 300–111 300)

8400 (2700–29 200)

50 600 (23 800–108 400)

9700 (4200–22 600)
3600 (1600–8200)

700 (300–1500)

400 (100–2600)

300 (100–900)

4300 (2000–7600)

2500 (1000–5300)

400 (200–800)

231 800 (114 100–455 000)

162 200 (70 200–394 400)

91 900 (44 800–187 800)

Data shown as posterior medians (95% posterior intervals) of GBS-related stillbirths, EOGBS cases, LOGBS cases, and infant deaths during iGBS in 2020 by region. The last
two digits in each number were rounded down, except for numbers less than 100, as done in previous estimates. EOGBS=early-onset iGBS. GBS=group B streptococcus.
iGBS=invasive GBS. LOGBS=late-onset iGBS.

Table 2: Sustainable Development Goal region estimates of acute and long-term outcomes

appendix p 39). In the appendix (p 40), we present a
sensitivity analysis without this assumption, whereby
58 300 (26 500–125 800) infants were estimated to die of
iGBS in 2020.
Using the country-specific stillbirth estimates for
the year 2019 by the UN and region-specific propor
tions of stillbirths caused by GBS infection
(appendix pp 36, 41), we estimate that globally, 46 200
(20 300–111 300) stillbirths resulted from in utero GBS
infection in 2020.
Of the patients who recovered from iGBS, 20·7%
(16·1–25·6) of those with GBS meningitis (all countries
combined), 3·3% (1·0–7·6) with GBS sepsis in highincome countries, and 9·2% (2·4–22·8) with GBS
sepsis in low-income and middle-income countries
are predicted to develop moderate or severe NDI, which
amounts to 37 100 children (14 600–96 200; figure 2B;
panel 2). Using the risk of moderate and severe NDI in
children with no history of iGBS15 as a counterfactual, we
also crudely estimated the excess number of children
with NDI due to iGBS, which was 30 400 (10 900–84 300;
appendix pp 13–16).
The risk of GBS maternal disease was 0·29 (0·15–0·47)
per 1000 deliveries and was assumed to be the same
in all countries. Note that no studies in this analysis were
done outside of Europe and North America. We applied
this risk to the country-specific numbers of births to
calculate the global number of maternal GBS cases:
40 500 (21 500–66 200; figure 2).
We estimated the meta-analytical odds ratio for the
association between maternal GBS colonisation and
prematurity to be 1·30 (1·02–1·71). We used countryspecific preterm risk estimates and our estimates of
maternal GBS colonisation prevalence to quantify the
excess number of preterm births associated with GBS
colonisation: 518 100 (36 900–1 142 300) globally, of which
172 300 (12 300–380 000) were in sub-Saharan Africa and
125 100 (8400–281 200) were in central and south Asia
(table 3); which corresponded to 3·5% (0·2–7·7%) of
preterm births globally.
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Discussion
We present the most comprehensive estimates to date,
to the best of our knowledge, of the global burden of
GBS disease related to pregnancy. Our results suggest
that the burden is even higher than previously quantified,
in part because of novel data enabling the estimation of
NDI cases after GBS sepsis and not just meningitis. It is
likely that more than 200 000 infants developed EOGBS,
and approximately 160 000 developed LOGBS in 2020.
Globally, 91 900 deaths were estimated to have occurred
in children with iGBS, with the highest numbers in
sub-Saharan Africa and Asia. More data on the risk of
moderate and severe NDI after GBS meningitis and
novel findings on NDI after GBS sepsis allowed for a
more comprehensive quantification of these outcomes.
New data from Africa and Asia also allowed for a
better estimation of stillbirths due to GBS.37 Finally, we
estimated the potential annual burden of GBS-associated
preterm births for the first time, at 0·5 million, with
a wide uncertainty range. Altogether, these results
highlight the large burden of GBS infection, better
informing public health action, especially for prevention,
and highlight a need for improved epidemiological data,
including prospective multicentre pregnancy cohort
studies in the highest burden regions, to reduce
uncertainty in estimates.
Infants in sub-Saharan Africa have the highest burden
of iGBS, with nearly half of all global GBS-related deaths
occurring there, reflecting high colonisation rates, a near
absence of intrapartum antibiotic prophylaxis policy
adoption, and a mortality due to GBS of 23% (12–38%).
Stillbirths caused by GBS are also high in sub-Saharan
Africa, whereas in Asia there are few data available on
GBS diagnosis in stillbirths. Of note, the stillbirth
outcome was modelled as the proportion with evidence
of GBS infection in a sterile site, and applied to the latest
UN estimates by country for stillbirth rate. We note that
the global estimated number of stillbirths has decreased
from 2·6 million38 in 2015 to the current 2 million since
we applied proportionate risk to the country-specific total
e813
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Figure 3: Region-specific relative distribution of GBS burden
(A) Cases of EOGBS and LOGBS as well as maternal iGBS. (B) Deaths during EOGBS or LOGBS and stillbirths. The map is coloured showing Sustainable Development
Goal regions. The areas of the pie charts are proportional to region-specific numbers. The pie charts present the proportions of cases in different regions that affect
babies and women. Posterior medians were used for each of the outcomes; uncertainty in the proportions is therefore not presented. EOGBS=early-onset iGBS.
GBS=group B streptococcus. iGBS=invasive GBS. LOGBS=late-onset iGBS.

numbers of stillbirths estimated by the UN for 2019, and
the apparent decrease in GBS stillbirth estimates is partly
because of lower UN stillbirth rate estimates. Given that
maternal GBS colonisation presumably is a necessary
step for GBS-related stillbirths, studies comparing the
stillbirth risk in pregnant women with GBS colonisation
versus pregnant women with no evidence of GBS
colonisation, and that adjust for potential confounders,
would probably improve the quantification of GBS
stillbirth risk. Notably, our estimates highlight the
importance of this public health problem, which in most
settings is unrecognised partly because of the limited
laboratory capacity to diagnose infections in stillbirths,
but also because of the absence of an investigation of the
causes of stillbirth, even in high-income settings.
e814

NDI risk after GBS sepsis was a major data gap,
and multicountry studies have allowed a more accurate
estimation of the long-term consequences of iGBS than
was feasible in the previous global estimate. On one
hand, the risk of moderate or severe NDI after GBS
sepsis is lower compared with the risk in children who
had GBS meningitis, with the risk of NDI after GBS
meningitis being similar to the risk after severe
neonatal meningitis due to any bacterial pathogen.39
On the other hand, since sepsis is a more common
presentation, our analysis suggests that the number of
moderate or severe NDI cases is probably considerably
higher than previously estimated. One limitation is that
most studies on NDI after iGBS did not include a
comparator group. As a crude approach to estimating
www.thelancet.com/lancetgh Vol 10 June 2022
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the excess number of moderate or severe NDI cases
due to GBS, we used the risk of NDI of children who
had no history of iGBS in Denmark as a counterfactual
risk. The risk was assumed to be fixed, ignoring the
uncertainty in this parameter and probable variation
that might occur in different settings. One metaanalysis of studies performed in low-income and
middle-income countries,40 for example, estimated a
lower prevalence of NDI in the general population in
some settings, whereas other data, collected using
sensitive tools for NDI assessment, suggest a higher
baseline risk of moderate or severe NDI than the
baseline risk estimated in the Denmark study (1–25%
in studies with more than ten participants.29 Another
limitation of our analysis is that different studies
recruited children at different ages and used different
NDI assessment tools or epidemiological designs,
which might partly explain the substantial betweenstudy variability in risk (appendix pp 29–32).
Furthermore, unlike the previous estimates, we did not
quantify neonatal encephalopathy with GBS to avoid
double counting.41 Notably, NDI after iGBS will deeply
affect children’s lives, in particular those with moderate
or severe impairment, as well as affect their parents,
and will have economic consequences to society
broadly. Our findings confirm the necessity of including
support to and aftercare for those who recover from
bacterial meningitis as one of the pillars of the
Defeating Meningitis roadmap.42
Prematurity has been shown to be associated with
GBS colonisation, and there are plausible mechanisms
for this.16,43 However, the most careful review to date
highlighted the heterogeneity in estimates of this
association from epidemiological studies, which might be
related to differences between studies in terms of the
timing of screening for GBS.10 Some cohort studies
assessed the exposure of GBS colonisation late in the
third trimester of pregnancy, hence missing preterm
births occurring earlier in pregnancy and potentially
underestimating the association. Given this challenge
and the wide uncertainty range, although in our analysis
we incorporated all the evidence available from
observational studies, our estimates of the associated
excess numbers need to be carefully interpreted. Although
the number appears to be high, it is a small proportion
(approximately 3·5%) of the approximately 15 million
preterm births each year. We note that, in addition,
preterm babies have a higher risk of iGBS, especially
LOGBS,44 which we have not estimated.
Maternal iGBS was estimated at 0·29 per 1000 births,
and a total of 40 500 cases per year, which might
represent a considerable proportion of all iGBS cases in
mothers and babies. However, all included studies were
from high-income countries and, by using these
data to represent all countries, we are likely to have
underestimated the magnitude of this public health
problem. Moreover, the few data on the fatality risk
www.thelancet.com/lancetgh Vol 10 June 2022

Panel 2: Estimated numbers of children with moderate
and severe neurodevelopmental impairment after
invasive group B streptococcus in 2020 by Sustainable
Development Goal region
•
•
•
•
•
•
•
•

Sub-Saharan Africa, 15 000 (5400–42 300)
North Africa and west Asia, 4900 (1800–13 200)
Central and south Asia, 6600 (2500–17 900)
East and southeast Asia, 6900 (2500–19 700)
Latin America and the Caribbean, 2100 (800–6500)
Oceania, 100 (30–400)
Europe and North America, 400 (200–900)
Global, 37 100 (14 600–96 200)

Data shown as posterior median and 95% posterior intervals.
The last two digits in each number were rounded down, as
done in previous estimates, except for numbers below 100.

Excess preterm births
Excess
preterm births associated with GBS
colonisation (numbers)
associated
with GBS
colonisation
(%)
Sub-Saharan Africa

4·0 (0·3–8·9)

172 300 (12 300–380 000)

North Africa and west
Asia

4·8 (0·4–10·6)

56 200 (4300–123 300)

Central and south Asia

2·6 (0·2–6·0)

125 100 (8400–281 200)

East and southeast Asia

2·7 (0·2–6·3)

68 500 (4900–157 200)

Latin America and the
Caribbean

3·9 (0·2–8·6)

38 800 (2800–85 700)

Oceania

4·7 (0·3–10·6)

Europe and North
America

5·1 (0·4–11·1)

Global

3·5 (0·2–7·7)

2800 (200–6400)
52 700 (3800–114 400)
518 100 (36 900–1 142 300)

Data shown as posterior medians (95% posterior intervals). The last two digits in
each number were rounded down, except for numbers less than 100, as was done
in previous estimates. GBS=group B streptococcus.

Table 3: Estimated numbers of preterm births associated with maternal
GBS colonisation in 2020 by Sustainable Development Goal region

during these episodes8 prevented the estimation of
maternal deaths, which might be higher where data are
absent.
Incidence of EOGBS reflects both the prevalence of
maternal GBS colonisation and the risk of disease in
babies born to mothers who are GBS colonised. By
inferring case numbers from these two sources, we
attempted to avoid the underestimation consistently
described for studies and routine data on EOGBS or
LOGBS incidence.6,7,27 In addition to our primary analysis,
we used a Bayesian evidence synthesis model that
combined direct incidence data with studies on maternal
GBS colonisation and EOGBS risk conditional on GBS
colonisation; this alternative approach resulted in a
slightly lower estimated incidence. More studies with
enhanced case capture, similar to one study in the UK, 45
e815
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and that also assess maternal GBS colonisation status
would allow for a direct comparison between these
approaches to inform burden estimation. Underascer
tainment and under-reporting also apply to LOGBS;
hence, we estimated the region-specific proportions of
iGBS cases occurring after the first week of life and
applied these to the estimated numbers of EOGBS cases
to calculate the LOGBS incidence. An underlying
assumption is that EOGBS and LOGBS are equally likely
to be identified in incidence studies; if EOGBS cases are
missed more often than LOGBS cases, it is possible that
our analysis might have overestimated the number of
LOGBS cases.
Our analyses have strengths and limitations. We were
able to advance the previous GBS global burden estimates,7
particularly with new studies on NDI from either highincome countries or low-income and middle-income
countries,29 which were funded as a result of the gaps
shown in the first study.15 The Bayesian approach has
many advantages compared with the previous estimation
approach, including the propagation of uncertainty for
several parameter estimates, although, as mentioned
earlier, a few of these parameters were assumed to be
fixed.
However, there are still some data gaps. The sample
sizes of some of the studies, in particular the studies on
NDI outcomes after GBS meningitis in low-income and
middle-income countries, were small, which highlights
the difficulty in performing these studies in some
settings and the need to improve surveillance to identify
those who recover from iGBS.29 Intrapartum antibiotic
prophylaxis coverage data are also few, and our analysis
is informed by a literature review with data
for 92 countries. Currently, our estimates do not
incorporate uncertainty for this variable; but a sensitivity
analysis (appendix pp 6–7) indicates how the
overestimation or underestimation of intrapartum anti
biotic prophylaxis coverage might have influenced
estimation. Studies that quantify intrapartum antibiotic
prophylaxis policy coverage in different countries would
improve our estimates and help to better capture
between-country variability. There were few data on
maternal iGBS and related maternal mortality. We also
did not quantify the global effect of iGBS on educational
needs for children with GBS-associated NDI, a problem
that was identified in a large cohort study in the
Netherlands,15 because data from different settings are
not available. Another limitation in our estimates is the
few data on fatality rates during iGBS for children who
have limited access to care and antibiotics. Although our
assumptions were similar to those made in previous
analyses, we also presented results where all children,
including those with limited access to care, were assumed
to have similar fatality rates during iGBS as those
reported in observational studies. Furthermore, for
parameters estimated at the global level (ie, assumed to
be the same for all countries), it is probable that the
e816

uncertainty was underestimated and point estimates
might have been biased when applied to specific settings.
For example, more data on NDI after GBS meningitis
were available for high-income countries, which implies,
in addition to the potential bias (eg, an underestimation
of NDI risk after GBS meningitis when this global risk is
applied to low-income settings), that uncertainty in
settings with fewer studies would be higher; data from
low-income and middle-income countries are necessary
to allow robust region-specific estimations. As is
common in many burden estimation exercises, the data
used to inform most outcomes were typically before the
year of estimation (2020) and might have been influenced
by the COVID-19 pandemic.
In summary, our estimates show that pregnancyrelated GBS results in a considerable disease burden
worldwide, with the highest absolute burden in subSaharan Africa and Asia. Effective interventions could
reduce the high incidence of iGBS, and prevent the
devastating long-term consequences on neurodevelop
ment, but also need to be implementable at high
coverage in the wide range of settings where GBS
infection is a public health problem; it is likely that
maternal GBS vaccines could be more scalable than
intrapartum antibiotic prophylaxis in the lowest resource
settings. Interventions that have a preventive effect
earlier in a pregnancy than intrapartum antibiotic
prophylaxis, which is given around the time of birth,
would have the added value of reducing stillbirths,
maternal infections, and potentially GBS-associated
preterm births. Our results can be used to refine costeffectiveness analyses regarding maternal GBS vaccines
under clinical development, through the inclusion of
NDI and other long-term consequences of infection, in
addition to mortality. Our data and analyses on NDI
underline the necessity of follow-up and providing care
to those who recover from iGBS. However, there are still
substantial data gaps. We hope that before another
round of estimates is undertaken, well designed studies
could address the top epidemiological data gaps
regarding stillbirths, maternal iGBS, and preterm risk.
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